Drug intelligence / Profile preview

ENB-002

Development stage: Preclinical
Lead developer: Alexion Pharmaceuticals
Modality: Small Molecules

Overview

ENB-002 is a preclinical-stage small molecule agonist of the glucagon-like peptide 1 receptor (GLP-1R), currently being developed by Endeavor BioMedicines for the treatment of obesity. As a small molecule targeting the GLP-1 receptor, it aims to provide a potentially oral alternative to the injectable peptide-based GLP-1 agonists currently on the market. The mechanism involves activating GLP-1R to regulate appetite and glucose metabolism, facilitating weight loss in patients with obesity.

Targets

GLP1R (GLP-1R)

Beyond the preview

Go deeper on ENB-002.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on ENB-002.

Explore the full profile